top of page

February 10th Webinar: Predictive Health Diagnostics $10M Pre-IPO Offering

Predictive Health Diagnostics $10M Pre-IPO Offering

Management Q&A Webinar This Wednesday, February 10th, at 1:00 PM PT

Boustead Securities, LLC (“Boustead”) presents its latest Pre-IPO offering, Predictive Health Diagnostics (“PHD”). PHD combines science, technology, proprietary analytics and clinical studies to detect cardiovascular disease and diabetes when it can be treated or more easily prevented.


Their Protein Unstable Lesion Signature Cardiac Test (“PULS Test”) measures protein biomarkers that indicate damage to the lining of the arteries – believed to be the earliest sign of coronary artery disease. The serum blood test helps to find people that are at risk of having a heart attack in the next 5 Years. PHD’s proprietary AI technology allows them to contemporaneously evaluate multiple relevant data types to identify clinically useful relationships that may be undetected by conventional methods. In 2016, PULS Test was the winner of the AABY Award for Innovation in Healthcare.


 

WEBINAR

Please join Doug Harrington, Founder and Chairman, and Matthew Nunez, CEO, for a Q&A Webinar this Wednesday, February 10th at 1:00 PM PT as they discuss how they can detect early forms of cardiovascular disease and diabetes.


Predictive Health Diagnostics Webinar

Wednesday, February 10th

1:00 PM PT


 

About Predictive Health Diagnostics

PHD develops, manufactures, and distributes unique diagnostic tests that can detect the early forms of cardiovascular disease and diabetes. Their PULS Test measures protein biomarkers that indicate damage to the lining of the arteries. The company was founded by medical professional Doug Harrington, who has 30+ year experience commercializing over 200 academic discoveries.

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com


Form CRS/Reg BI Disclaimer:

Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.


Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

Boustead Securities Client Nano-C Inc., Announces Signed Letter of Intent with Unify Pharmaceuticals

Boustead Securities Client, Nano-C, Inc., Announces Signed Letter of Intent with Unify Pharmaceuticals to Pursue Strategic Partnership for Parkinson’s and COVID-19 Indications


Nano-C’s Unique Chemistry is a Key Enabler for Potential Drug Efficacy

in Broad Range of Treatments



Boustead Securities, LLC (“Boustead”) client, Nano-C, Inc. (“Nano-C” or the “Company”), a leading producer of patented specialty active ingredients and formulations, announces a signed Letter of Intent (LOI) to pursue a strategic partnership with Unify Pharmaceuticals, a Vanderbilt University spinout co-founded by Dr. Laura Dugan (Vanderbilt, Washington University, Stanford, MIT). Unify is set to begin Phase 1 clinical trials this year for drug therapies for neurodegenerative disease as well as fast-track clinical trials for treatment of COVID-19.

Nano-C and Unify have had a growing and active business relationship for several years and are pleased to formalize their strategic partnership. As Unify’s chemistry partner, Nano-C will manage the scale up and synthesis of a functionalized fullerene identified as UP-1007, Unify’s active pharmaceutical ingredient (API), at an exacting cGMP standard. Nano-C and Unify intend to execute a Contract Manufacturing and Supply Agreement covering the preparation for and completion of Phase I and fast-track clinical trials.

Dr. Dugan has studied the therapeutic properties of functionalized fullerenes for over 20 years and has published numerous scientific papers on the potential benefits of these unique APIs on neurodegenerative disease including Parkinson’s and Alzheimer’s. Pre-clinical trials showed marked efficacy on primates afflicted with Parkinson’s Disease, with statistically significant differences appearing after just 30 days vs the control with no toxicity over the course of the trial. Data from Dr. Dugan’s research is being leveraged for a possible COVID-19 drug therapy.


Fullerenes are small molecules that can be customized for use in a wide range of therapeutic applications. Their versatility stems from their fundamental molecular properties and by applying functional chemistry to their surface, they become a true molecular platform that potentially enables strong anti-viral and anti-inflammatory properties to affect a new class of therapeutics.

Nano-C and Unify are in the process of negotiating a term sheet to pursue a strategic alliance. This strategic partnership marks Nano-C’s market expansion into biopharmaceuticals and gives Unify access to Nano-C’s leading-edge organic chemists for the optimization of UP-1007 and next generation APIs, and at the volumes and quality required during the clinical trial phase and into commercialization.



This press release is not a solicitation or offer to buy or sell securities. For illustrative purposes only. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.

 

About Nano-C, Inc. Nano-C is a leading innovator and manufacturer in the chemistry of nanostructured carbon, including fullerenes, carbon nanotubes (CNT), and their chemical derivatives. Nano-C is focused on fundamental technology trends: the roll-out of 5G, connectivity driven by the Internet of Things, the race to extend Moore’s Law, the move to address climate change through sustainable energy generation and now healthcare.  Proprietary materials produced by Nano-C are critical links in the value chain for next-generation electronics, sensors, semiconductor manufacturing and biopharmaceuticals. Nano-C’s advanced materials and molecular platform encompasses a portfolio of unique solutions protected by over 150 global patents across 46 patent families. Through its patented products and processes, and its distinct competencies in the chemistry of these materials, Nano-C is enabling a revolution in device design, manufacture, and performance, and it is committed to their responsible development and use. For more information, please visit our website at www.nano-c.com.  About Unify Pharmaceuticals Unify Pharmaceuticals is a biotech company utilizing the latest scientific discoveries to develop drugs targeting neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s and Strokes. The company is the culmination of over 20 years’ research into UP-1007 and related molecules.  UP-1007 is the first-in-class water-soluble fullerene that has been shown to successfully address the underlying causes of Parkinson’s and other diseases involving oxidative damage. For more information please visit www.unifypharma.com. About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. About Sutter Securities Group, Inc. Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com. Forward-Looking Statements This document contains forward-looking statements.  In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

Boustead Securities Client, Know Labs, Enters into Research Agreement with Mayo Clinic


Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (“Know Labs” or the “Company”) (OTC: KNWN), an emerging leader in non-invasive medical diagnostics, announced that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor (CGM).

Phil Bosua, Know Labs CEO, stated, “We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBAND CGM.”


In May 2020, Boustead aided Know Labs in closing a private placement with an aggregate total of $5,739,500. Know Labs aims to create non-invasive biosensors capable of detecting and measuring biomolecules continuously. This has applications for a new area of personal health and medicine that may allow issues derived from abnormal blood glucose, hormone, medications, and metabolite levels to be discovered in real time. Know Labs has a foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place.  Know Labs plans to initially enter the diabetic Continuous Glucose Monitoring (CGM) market with its UBAND non-invasive CGM product; and to later enter other clinical monitoring markets for continuous, non-invasive hormone, metabolite, and biomolecular monitoring. Contact Pete Conley for more information Managing Director Head of Intellectual Property (IP) Banking (310) 383-7874 pete@boustead1828.com

 

This press release is not an offer to buy or solicit securities. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of total loss. There is no guarantee that any specific outcome will be achieved.


About Know Labs, Inc. Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first planned product is the non-invasive UBAND™ Continuous Glucose Monitor (CGM). Those wishing to stay up to date on the developments at Know Labs can subscribe to the Company’s YouTube channel at this link. For more information, visit the company’s website at www.knowlabs.co.


About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

bottom of page